Table 2.
Multivariable Cox’s regression analyses for OS in 301 untreated patients
| Variable | Adjusted HR | 95% CI | P value* |
|---|---|---|---|
| HR+/HER2+ | 1.1 | (0.55–2.07) | 0.84 |
| TNBC | 0.68 | (0.40–1.18) | 0.17 |
| HER2+ | 0.69 | (0.29–1.58) | 0.37 |
| Age at diagnosis > 50 | 2.22 | (1.35–3.64) | 0.0017 |
| Histology lobular | 1.36 | (0.84–2.20) | 0.21 |
| T Stage | |||
| T2 | 1.71 | (0.73–3.98) | 0.21 |
| T3 | 0.36 | (0.06–1.98) | 0.24 |
| T4 | 1.31 | (0.17–9.73) | 0.79 |
| N Stage | |||
| N1 | 1.34 | (0.64–2.81) | 0.44 |
| N2 | 0.5 | (0.07–3.69) | 0.5 |
| Invasive tumor size | 1.15 | (0.93–1.43) | 0.2 |
| Number of positive nodes | 1.11 | (1.04–1.18) | 0.0008 |
| Grade II | 1.07 | (0.73–1.59) | 0.72 |
| Grade III | 1.38 | (0.82–2.32) | 0.23 |
| Stage II | 0.84 | (0.35–1.93) | 0.66 |
| Stage III | 3.64 | (0.48–27.45) | 0.21 |
CI confidence interval, HR hazard ratio, OS overall survival, TNBC triple-negative breast cancer
*HR+/HER2− subtype used as reference for comparison with other three subtypes. P < 0.05 was considered statistically significant